• Latest Posts

ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial

Can this British Biotech Overcome Failure buying drugs from AstraZeneca?

The 8 Biggest Biotech Medical Fails of 2016 in Europe

June was a Tough Month for European Biotech… #Fail


Allergy Immunotherapy Knocked Out in Phase III by an ‘Overperforming Placebo’

UK Immunotherapy against Grass Allergies moves on to Phase III Trials

It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund

2014, the Biggest Year Ever for European Biotech IPOs